GlassScriptPhysician profile
Stacy Horn
NPI 1962851121
$2,999.36
in general payments reported to CMS, 2019-2025
27 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.19 · 2022: $92.41 · 2023: $1,367 · 2024: $996 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.61 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.80 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $390.77 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.93 | 2023-2024 | Caplyta |
| Novo Nordisk INC | $333.19 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $277.26 | 2022-2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $170.56 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $131.72 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $113.26 | 2023-2024 | |
| Amgen INC. | $106.17 | 2022-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $65.73 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Dynavax Technologies Corporation | $59.21 | 2023-2024 | Heplisav-B |
| Abbott Laboratories | $58.84 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $58.35 | 2025 | |
| Exact Sciences Corporation | $51.06 | 2023-2024 | Cologuard Collection Kit |
| Corium, LLC | $48.74 | 2024-2025 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $37.18 | 2022-2023 | Unithroid |
| Cardiva Medical, INC. | $36.32 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boston Scientific Corporation | $29.97 | 2025 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $20.06 | 2025 | Rexulti |
| Lundbeck LLC | $18.52 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.05 | 2024 | Voquezna |
| Antares Pharma, INC. | $17.74 | 2025 | Xyosted |
| Dexcom, INC. | $16.62 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $15.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.10 | 2022 | |
| Pfizer INC. | $13.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.